Intellipharmaceutics International Inc. (IPCI) SEC Filing 6-K Foreign Issuer report for the period ending Tuesday, December 4, 2018

Intellipharmaceutics International Inc.

CIK: 1384943 Ticker: IPCI

View differences made from one to another to evaluate Intellipharmaceutics International Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Intellipharmaceutics International Inc..


Assess how Intellipharmaceutics International Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Intellipharmaceutics International Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Intellipharmaceutics International Inc. provided additional information to their SEC Filing as exhibits

Ticker: IPCI
CIK: 1474835
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001654954-18-013578
Submitted to the SEC: Tue Dec 04 2018 9:53:54 PM EST
Accepted by the SEC: Wed Dec 05 2018
Period: Tuesday, December 4, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: